Vertex Pharmaceuticals Incorporated (VRTX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $558.56 (+3.41%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Joon Lee | Truist Financial | $525.00 | -6.0% |
| Mar 10, 2026 | Akash Tewari | Jefferies | $580.00 | +3.8% |
| Mar 2, 2026 | Evan David Seigerman | BMO Capital | $600.00 | +7.4% |
| Feb 17, 2026 | Eliana Merle | Barclays | $607.00 | +8.7% |
| Feb 17, 2026 | Andrew Fein | H.C. Wainwright | $591.00 | +5.8% |
| Feb 13, 2026 | Terence Flynn | Morgan Stanley | $570.00 | +2.0% |
| Feb 13, 2026 | Louise Chen | Scotiabank | $558.00 | -0.1% |
| Feb 13, 2026 | Paul Matteis | Stifel Nicolaus | $466.00 | -16.6% |
| Feb 13, 2026 | Andrew Fein | H.C. Wainwright | $518.00 | -7.3% |
| Jan 23, 2026 | Cory Kasimov | Evercore ISI | $530.00 | -5.1% |
| Jan 22, 2026 | Brian Abrahams | RBC Capital | $546.00 | -2.2% |
| Jan 6, 2026 | Michael Yee | UBS | $535.00 | -4.2% |
| Dec 3, 2025 | Terence Flynn | Morgan Stanley | $516.00 | -7.6% |
| Nov 4, 2025 | Carter Gould | Cantor Fitzgerald | $485.00 | -13.2% |
| Nov 4, 2025 | Gena Wang | Barclays | $414.00 | -25.9% |
| Aug 5, 2025 | Eliana Merle | UBS | $553.00 | -1.0% |
| Jun 17, 2025 | Brian Abrahams | RBC Capital | $420.00 | -24.8% |
| May 6, 2025 | Greg Harrison | Scotiabank | $442.00 | -20.9% |
| Jan 31, 2025 | Evan Seigerman | BMO Capital | $545.00 | -2.4% |
| Jan 30, 2025 | Mohit Bansal | Wells Fargo | $460.00 | -17.6% |
Top Analysts Covering VRTX
VRTX vs Sector & Market
| Metric | VRTX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.25 | 2.25 | 2.41 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +2.7% | +153002.0% | +21.5% |
| P/E Ratio | 33.13 | 3.44 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.34B | $3.45B | $3.55B | 11 |
| 2027-03-31 | $3.22B | $3.32B | $3.42B | 11 |
| 2027-06-30 | $3.37B | $3.48B | $3.57B | 7 |
| 2027-09-30 | $3.51B | $3.63B | $3.73B | 8 |
| 2027-12-31 | $3.57B | $3.68B | $3.79B | 7 |
| 2028-12-31 | $15.99B | $15.99B | $15.99B | 23 |
| 2029-12-31 | $16.80B | $17.82B | $19.32B | 11 |
| 2030-12-31 | $18.65B | $19.78B | $21.44B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $4.87 | $5.08 | $5.26 | 5 |
| 2027-03-31 | $4.63 | $4.83 | $5.00 | 5 |
| 2027-06-30 | $5.00 | $5.22 | $5.40 | 5 |
| 2027-09-30 | $5.55 | $5.79 | $6.00 | 5 |
| 2027-12-31 | $5.70 | $5.94 | $6.16 | 5 |
| 2028-12-31 | $14.05 | $25.05 | $35.54 | 13 |
| 2029-12-31 | $27.15 | $29.34 | $32.54 | 11 |
| 2030-12-31 | $30.87 | $33.36 | $37.00 | 5 |
Frequently Asked Questions
What is the analyst consensus for VRTX?
The consensus among 16 analysts covering Vertex Pharmaceuticals Incorporated (VRTX) is Buy with an average price target of $559.33.
What is the highest price target for VRTX?
The highest price target for VRTX is $607.00, set by Eliana Merle at Barclays on 2026-02-17.
What is the lowest price target for VRTX?
The lowest price target for VRTX is $175.00, set by Geoff Porges at Leerink Partners on 2021-12-02.
How many analysts cover VRTX?
16 analysts have issued ratings for Vertex Pharmaceuticals Incorporated in the past 12 months.
Is VRTX a buy or sell right now?
Based on 16 analyst ratings, VRTX has a consensus rating of Buy (2.25/5) with a +2.7% upside to the consensus target of $559.33.
What are the earnings estimates for VRTX?
Analysts estimate VRTX will report EPS of $5.08 for the period ending 2026-12-31, with revenue estimated at $3.45B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.